-
Founded in:
1995-07-26 -
Country:
China -
Address:
Lianyungang Economic and Technological Development Zone, Jiangsu Province -
Tax NO.:
913207006083959289 -
Registered Funds:
1,000,000,000 Yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cephalexin |
It inhibits bacterial cell wall synthesis and has good antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis, various groups of streptococci, Streptococcus pneumoniae, some Escherichia coli, Klebsiella, Proteus mirabilis and Haemophilus influenzae. It also has good antibacterial effect on penicillin-resistant Staphylococcus aureus.
More
It inhibits bacterial cell wall synthesis and has good antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis, various groups of streptococci, Streptococcus pneumoniae, some Escherichia coli, Klebsiella, Proteus mirabilis and Haemophilus influenzae. It also has good antibacterial effect on penicillin-resistant Staphylococcus aureus. |
15686-71-2 | 33 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Repaglinide |
Not yet clear
More
Not yet clear |
135062-02-1 | 43 | |
| Metformin |
Not yet clear
More
Not yet clear |
657-24-9 | 0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Repaglinide |
Not yet clear
More
Not yet clear |
135062-02-1 | 43 | |
| Metformin |
Not yet clear
More
Not yet clear |
657-24-9 | 0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Morinidazole |
Extract from the above information
More
Extract from the above information |
92478-27-8 | 21 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Repaglinide |
Repaglinide is a short-acting insulin secretagogue that lowers blood sugar levels by promoting the release of insulin from the pancreas. This effect depends on functional beta cells in the pancreatic islets. Repaglinide binds to receptors on beta cells to close ATP-dependent potassium channels in the beta cell membrane, depolarizes beta cells, opens calcium channels, and increases the influx of calcium, thereby inducing beta cells to secrete insulin. After oral administration of repaglinide, patients with type 2 diabetes experience an insulin secretion response within 30 minutes after a meal, causing blood sugar to drop during meals. Plasma repaglinide levels drop rapidly, and 4 hours after taking the drug, the drug concentration in the plasma of patients with type 2 diabetes is very low. Studies have shown that when patients with type 2 diabetes take 0.5-4 mg of repaglinide, blood sugar concentrations decrease in a dose-dependent manner.
More
Repaglinide is a short-acting insulin secretagogue that lowers blood sugar levels by promoting the release of insulin from the pancreas. This effect depends on functional beta cells in the pancreatic islets. Repaglinide binds to receptors on beta cells to close ATP-dependent potassium channels in the beta cell membrane, depolarizes beta cells, opens calcium channels, and increases the influx of calcium, thereby inducing beta cells to secrete insulin. After oral administration of repaglinide, patients with type 2 diabetes experience an insulin secretion response within 30 minutes after a meal, causing blood sugar to drop during meals. Plasma repaglinide levels drop rapidly, and 4 hours after taking the drug, the drug concentration in the plasma of patients with type 2 diabetes is very low. Studies have shown that when patients with type 2 diabetes take 0.5-4 mg of repaglinide, blood sugar concentrations decrease in a dose-dependent manner. |
135062-02-1 | 43 |